On the basis of previous studies (Li et al., 1995), we hypothesize that cancer cells in the high GTscore subtype secrete the immunosuppressive molecule sGD2 (Ladisch et al., 1987), which inhibits T-cell proliferation and therefore likely contributes to immunotherapy resistance. Here, SMARCD2 is linked to cancer.